吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究  

The Clinical Study of Combonation Chemotherapy with Gemcitabine and Cisplatin in the Treatment of Advanced Non-small

作　　者：隋捷[1] 刘积良[1] 段寅[1] 

机构地区：[1]深圳市第二人民医院肿瘤科,广东省深圳市518035

出　　处：《中国肿瘤临床》2004年第23期1349-1350,1353,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:比较晚期非小细胞肺癌采用吉西他滨加顺铂与长春瑞宾加顺铂化疗的疗效。方法:80例晚期非小细胞肺癌患者分为两组,A组(40例采用吉西他滨加顺铂联合化疗);B组(40例采用长春瑞宾加顺铂化疗),进行疗效分析。结果:A组CR4例,PR20例,总有效率60.0%,B组CR2例,PR13例,总有效率37.5%。统计学比较,两组具显著性差异(P<0.05)。A组中位生存期9.5个月,B组6.3个月。主要不良反应为不同程度的白细胞、血小板、血色素下降,B组均较A组明显(P<0.05)。结论:吉西他滨加顺铂治疗晚期非小细胞肺癌疗效明确,耐受性好。Objective: To compare the effect of combination chemotherapy between Gemcitabine plus Cisplatin regimen and Vinorelbine plus Cisplatin regimen in the treatment of advanced Non-small cell lung cancer. Methods: 80 patients with advanced non-small cell lung cancer were dividede into two groups. Group A (40 cases) were treated with Gemcitabine plus Cisplatin regimen and group B (40 cases) were treated with Vinorelbine plus Cisplatin regimen. Results: Complete response in 4 patients and partial response in 20 were observed with an overall response rate of 60% in group A. Complete response in 2 patients and partial response in 13 were observed with an overall response rate of 37.5% in group B (P<0.05). SR was 9.5 months in group A compared to 6.3 months in group B. Neutropenia, thrombocytopenia and aneia in group B were more serious than those in group A(P<0.05). Conclusion: The study demonstrate that Gemcitabine plus Cisplatin regimen is effective and safe.

关 键 词：吉西他滨 顺铂 长春瑞宾 联合化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]